These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 36514034)
1. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial. Schöffski P; George S; Heinrich MC; Zalcberg JR; Bauer S; Gelderblom H; Serrano C; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Becker C; Shi K; Meade J; Ruiz-Soto R; Blay JY; von Mehren M BMC Cancer; 2022 Dec; 22(1):1302. PubMed ID: 36514034 [TBL] [Abstract][Full Text] [Related]
2. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Blay JY; Serrano C; Heinrich MC; Zalcberg J; Bauer S; Gelderblom H; Schöffski P; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Shi K; Ruiz-Soto R; George S; von Mehren M Lancet Oncol; 2020 Jul; 21(7):923-934. PubMed ID: 32511981 [TBL] [Abstract][Full Text] [Related]
3. Ripretinib for the treatment of advanced gastrointestinal stromal tumor. Zalcberg JR Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116 [TBL] [Abstract][Full Text] [Related]
4. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977 [TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. Gelderblom H; Jones RL; Blay JY; George S; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Harrow B; Becker C; Reichmann W; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S; Eur J Cancer; 2023 Oct; 192():113245. PubMed ID: 37598656 [TBL] [Abstract][Full Text] [Related]
6. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study. Symcox M; Somaiah N Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454 [TBL] [Abstract][Full Text] [Related]
7. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy. Fung S; Shirley M Drugs; 2022 Oct; 82(15):1541-1548. PubMed ID: 36282417 [TBL] [Abstract][Full Text] [Related]
8. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371 [TBL] [Abstract][Full Text] [Related]
9. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590 [TBL] [Abstract][Full Text] [Related]
10. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. George S; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Razak AA; Gordon MS; Somaiah N; Jennings J; Meade J; Shi K; Su Y; Ruiz-Soto R; Janku F Eur J Cancer; 2021 Sep; 155():236-244. PubMed ID: 34391056 [TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor. Kumar V; Doros L; Thompson M; Mushti SL; Charlab R; Spehalski EI; Zhao H; Thompson MD; Tang S; Pazdur R; Lemery SJ; Theoret MR; Fashoyin-Aje LA Clin Cancer Res; 2023 Jun; 29(11):2020-2024. PubMed ID: 36485007 [TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study. Yang W; Qian H; Yang L; Wang P; Qian H; Chu B; Liu Z; Sun J; Wu D; Sun L; Zhou W; Hu J; Chen X; Shou C; Ruan L; Zhang Y; Yu J Front Oncol; 2023; 13():1180795. PubMed ID: 37274264 [TBL] [Abstract][Full Text] [Related]
14. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817 [TBL] [Abstract][Full Text] [Related]
15. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial. Symcox M; Jones RL Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164 [TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020 [TBL] [Abstract][Full Text] [Related]
17. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report. Wu C; Zhang J; Wu X Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435 [TBL] [Abstract][Full Text] [Related]
18. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors. Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853 [TBL] [Abstract][Full Text] [Related]
19. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience. Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN Front Oncol; 2022; 12():883399. PubMed ID: 35847924 [TBL] [Abstract][Full Text] [Related]
20. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China. Zhang X; Zhang P; Qiu H; Fang Y; Liu H; Zhou Y; Xu H; Yu J; Zhang J; Wang M; Shen L; Li J Adv Ther; 2023 Sep; 40(9):3817-3829. PubMed ID: 37356078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]